trial · primary record
Azacitidine
Acute Myeloid Leukemia
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 335 |
| Primary completion | 2027-03-31 |
| Primary endpoint | Minimal residual disease (MRD) response (Arm 1, 2, 4 and 5) |
| Registry ID | NCT05554406 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:28:58.464Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05554406
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.